期刊
EMBO JOURNAL
卷 35, 期 18, 页码 2026-2044出版社
WILEY
DOI: 10.15252/embj.201592903
关键词
beta cell; diabetes; insulin; regeneration; zebrafish
资金
- Ragnar Soderberg's foundation
- Swedish Research Council
- Swedish Foundation for Strategic Research
- Wallenberg Institute for Regenerative Medicine
- Strategic Research Programme in Stem Cell Research and Regenerative Medicine at the Karolinska Institutet
- Wenner-Gren Foundation
- Stockholm County Council
- Family Erling-Persson Foundation
- Berth von Kantzows Foundation
- Swedish Council for Working Life and Social Research
- Swedish Diabetes Association
- Novo Nordisk Scandinavia
- GlaxoSmithKline
- Carl Trygger's foundation
There is great interest in therapeutically harnessing endogenous regenerative mechanisms to increase the number of beta cells in people with diabetes. By performing whole-genome expression profiling of zebrafish islets, we identified 11 secreted proteins that are upregulated during beta-cell regeneration. We then tested the proteins' ability to potentiate beta-cell regeneration in zebrafish at supraphysiological levels. One protein, insulin-like growth factor (Igf) binding-protein 1 (Igfbp1), potently promoted beta-cell regeneration by potentiating alpha -to beta-cell transdifferentiation. Using various inhibitors and activators of the Igf pathway, we show that Igfbp1 exerts its regenerative effect, at least partly, by inhibiting Igf signaling. Igfbp1's effect on transdifferentiation appears conserved across species: Treating mouse and human islets with recombinant IGFBP1 in vitro increased the number of cells co-expressing insulin and glucagon threefold. Moreover, a prospective human study showed that having high IGFBP1 levels reduces the risk of developing type-2 diabetes by more than 85%. Thus, we identify IGFBP1 as an endogenous promoter of beta-cell regeneration and highlight its clinical importance in diabetes.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据